Trading over 12 years, with an emphasis in small cap biotech. Passionate about science and cooking. "Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."Ed Seykota
MSc Project Management Graduate 2012, PRINCE2 Practitioner, APMP, Winner of APM Scottish Project Challenge 2012, Recipient of Technology Strategy Board start-up Grant 2013. Risk Management Product of the year 2013 with Datatecnics. Risk Management Innovation of the year 2015 with Datatecnics (beating Google!) Specialisms: Projects - especially how they relate to strategy; start-up phase; business case design; Supply Chains Direct message me here or on: LinkedIn: http://www.linkedin.com/in/ABHussain New Twitter account: @AbuB_Hussain
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
An independent analyst and private investor. Based in Warsaw, Poland (Europe). Professional experience comprises about 20 years in a number of financial and industrial companies. Fan of the Austrian School of Economics.
Blog: Simple Digressions (daily analysis of the precious metals market; general investment issues; sometimes articles on demand of my readers).
Robert Hauver publishes The Double Dividend Stock Alert, a monthly investment newsletter that features the best dividend stocks and option selling strategies for income investors.
TipRanks rates DoubleDividendStocks in the Top 25 of all financial bloggers.
The https://www.DoubleDividendStocks.com website also features High Dividend Stocks By Sector Tables, and Covered Calls & Cash Secured Puts Tables, a Dividend Stocks blog, and a a Stock Market News & Data page. 845-225-4094
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
I am now retired from the US pharma industry having spent over 33 years in the Mid-Atlantic corridor in Sales(Hospital mainly), Scientific Relations and Managed Care/LTC. I worked at BMY, Bayer/Miles Labs and SGP/MRK prior to early retirement..
Today I enjoy investing in Bio-Pharmas mostly, because it is what I know best!
I invest mostly in large companies such as BMY, PFE, MRK, GSK, and JNJ (love the divis) but I like the up and coming Bios like CLDX. Cancer and Immunotherapy intrigues me..so I have made that a major consideration since 2008....With BARDA,the GAIN act and QDIP Ive come to appreciate the Antibiotic cos.and have made them a major component of my LT strategy to build wealth while in Retirement....Ive invested in Trius(TSRX),CBST, CEMP, DRTX, TTPH, CTIX and just added AKAO.....
I manage personal monies and some family members..gratis of course!
My name is Tarun Chandra, and I've been an Analyst on both Buyside and Sellside. In addition, I've worked in Corporate Strategy and Finance roles for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for individual investors. Prudent Biotech portfolio is a quantitative-driven systematic investing product. More can be learnt at the website https://PrudentBiotech.com and from our Blog https://PrudentBiotech.com/blog.
Joseph has been an analyst, investor, and student of economic theory; money and banking; and statistical methods for evaluating and implementing risk/reward trading algorithms since 1972. Joseph is also an occasional contributor to financial publications and his essays are frequently cited by other financial websites and publications.
Since the end of the Great Recession, Joseph came to recognize that traditional methodologies for forecasting economic growth and investment asset pricing are no longer of value, and a broader understanding of the post Glass Steagall, financially engineered world that has driven markets and economies since the turn of the century is required today.
He has a good grasp of Shadow Banking, High Frequency Trading, and Dark Pools, and their impact on today’s markets. He has also spent considerable time understanding the new global paradigm of central bank involvement in experimental policy designed to better control economies.
Joseph doesn’t subscribe to a specific school of theory on economics. Rather, his thinking is based on a combination of the Classical School, the Austrian School, and the Keynesian School. He even sees the writings of Karl Marx as particularly instructive.
Joseph is particularly fond of the following quote from Albert Einstein and sees his own work as driven by that same passionate curiosity that Einstein refers to:
“I have no special talents. I am only passionately curious.”
Coming in a close second in terms of favorite quotes that express his views, Joseph embraces Lord Acton’s views expressed here:
“The danger is not that a particular class is unfit to govern.
Every class is unfit to govern."
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
My formal education ended with a Ph.D. in Biochemistry, minor in Organic Chemistry. After roughly two decades in academic research, my real-world education has continued at two biotech-related companies.
Yoel Minkoff is a news editor at Seeking Alpha, which he joined in 2014 after working on the Press Desk at Moody's Investors Service. Prior to Moody's, Yoel was a Financial Analyst at Merrill Lynch.
Portfolio Analyst at Phyto Partners
"Phyto Partners is a venture capital fund that invests in businesses that operate in and around the burgeoning cannabis industry. The Phyto team provides strategic business resources to companies that participate in the business of Cannabis."
Bill is Chief Investment Officer of Luby Asset Management LLC, an investment management company in Tiburon, California. He also publishes the VIX and More (http://vixandmore.blogspot.com/) blog and an investment newsletter. His research and trading interests focus on volatility, market sentiment, technical analysis, ETPs and options. Bill was previously a business strategy consultant. When not trading or blogging, he can often be found running, hiking, and kayaking in Northern California. Bill has a BA from Stanford University and an MBA from Carnegie-Mellon University. Visit Bill's blog, VIX and More (http://vixandmore.blogspot.com/)
Whitney Tilson is the founder and Managing Partner of Kase Capital Management, which manages three value-oriented hedge funds. Mr. Tilson is also the co-founder of Value Investor Insight, an investment newsletter.
Mr. Tilson has co-authored two books, The Art of Value Investing: How the World's Best Investors Beat the Market (2013) and More Mortgage Meltdown: 6 Ways to Profit in These Bad Times (2009), was one of the authors of Poor Charlie’s Almanack, the definitive book on Berkshire Hathaway Vice Chairman Charlie Munger, and has written for Forbes, the Financial Times, Kiplinger’s, the Motley Fool and TheStreet.com. He was featured in two 60 Minutes segments in December 2008 about the housing crisis (which won an Emmy) and in March 2015 about Lumber Liquidators. He served for two years on the Board of Directors of Cutter & Buck, which designs and markets upscale sportswear, until the company was sold in early 2007.
Mr. Tilson received an MBA with High Distinction from the Harvard Business School, where he was elected a Baker Scholar (top 5% of class), and graduated magna cum laude from Harvard College, with a bachelor’s degree in Government.
Mr. Tilson spent much of his childhood in Tanzania and Nicaragua (his parents are both educators, were among the first couples to meet and marry in the Peace Corps, and have retired in Kenya). Consequently, Mr. Tilson is involved with a number of charities focused on education reform and Africa. For his philanthropic work, he received the 2008 John C. Whitehead Social Enterprise Award from the Harvard Business School Club of Greater New York. He is a member and past Chairman of the Manhattan chapter of the Young Presidents’ Organization. Mr. Tilson lives in Manhattan with his wife and three teenage daughters.
Over forty five years of investing experience. Three Master's degrees. Retired, except for some rental real estate. Serve on three professional boards dealing with property management and regional symphony orchestras. Play in a super regional symphony orchestra and regional professional concert band. On SA to learn, have fun and tweak some egos..especially progressive dimwits.
Disciple of Harry Browne's portfolio system (income, permanent and speculative) with real estate and other income streams. It works.